Clinical Trial Update: Debio 0123 in Combination With Carboplatin and Etoposide in Adult Participants With Small Cell Lung Cancer That Recurred or Progressed After Previous Standard Platinum-Based Therapy [Phase 1]

View source ↗

Summary

Phase 1 trial update evaluating Debio 0123 in combination with carboplatin and etoposide in adults with small cell lung cancer that recurred or progressed after…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• Debio 0123
• Etoposide (Etoposide)

Snippet

Sponsor: Debiopharm International SA | Conditions: Small Cell Lung Cancer Recurrent | Phase 1 | Status: ACTIVE_NOT_RECRUITING